Lilly Pleads Guilty To Off-Label Evista Promotion
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will pay a $36 mil. fine for promoting the osteoporosis drug for reduction in breast cancer risk.
You may also be interested in...
Evista Approval For Breast Cancer Risk Reduction Comes With “Black Box” On VTE, Stroke
Lilly’s osteoporosis drug is cleared for use in reducing the risk of invasive breast cancer in two female patient populations.
Evista Approval For Breast Cancer Risk Reduction Comes With “Black Box” On VTE, Stroke
Lilly’s osteoporosis drug is cleared for use in reducing the risk of invasive breast cancer in two female patient populations.
Investigation Into Cephalon’s Actiq Winding Down
Connecticut Attorney General’s office will meet with Cephalon next month to discuss marketing of the pain medication.